Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Research

• Publication date

  2010-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-09-3573PMID 20501833PMCID PMC2889008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents.

  2012cited by this paper
• Abstract #2490: Targeting the replication checkpoint with a potent and selective CHK1 inhibitor

  2009cited by this paper
• Single-Strand Annealing, Conservative Homologous Recombination, Nonhomologous DNA End Joining, and the Cell Cycle-Dependent Repair of DNA Double-Strand Breaks Induced by Sparsely or Densely Ionizing Radiation

  2009cited by this paper
• Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

  2009cited by this paper
• Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

  2009influential reference
• The Complexity of Double-Strand Break Ends is a Factor in the Repair Pathway Choice

  2009cited by this paper
• The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer

  2008cited by this paper
• Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

  2008cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008cited by this paper
• Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil

  2008cited by this paper
• DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

  2008cited by this paper
• Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review

  2008cited by this paper
• Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  2008cited by this paper
• A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

  2008cited by this paper
• G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

  2008cited by this paper
• Inhibitors of checkpoint kinases: from discovery to the clinic.

  2007cited by this paper
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• The Relationship of Premature Mitosis to Cytotoxicity in Response to Checkpoint Abrogation and Antimetabolite Treatment

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Molecular pathogenesis of pancreatic cancer.

  2006cited by this paper
• Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

  2005cited by this paper
• The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

  2005cited by this paper
• Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

  2005cited by this paper
• Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology

  2005cited by this paper
• Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.

  2005cited by this paper
• Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway.

  2005cited by this paper
• Detection of Histone H2AX Phosphorylation on Ser‐139 as an Indicator of DNA Damage (DNA Double‐Strand Breaks)

  2004cited by this paper
• Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation

  2004cited by this paper
• Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53

  2004cited by this paper
• Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress*

  2003cited by this paper
• Caffeine Could Not Efficiently Sensitize Homologous Recombination Repair-Deficient Cells to Ionizing Radiation-Induced Killing

  2003cited by this paper
• Selective targeting of homologous DNA recombination repair by gemcitabine.

  2003cited by this paper
• Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

  2002cited by this paper
• Molecular pathogenesis of pancreatic cancer.

  2002cited by this paper
• Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

  2002cited by this paper
• Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

  2001cited by this paper
• The Radioresistance to Killing of A1–5 Cells Derives from Activation of the Chk1 Pathway*

  2001cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma

  2000cited by this paper
• Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.

  2000cited by this paper
• Rapid destruction of human Cdc25A in response to DNA damage.

  2000cited by this paper
• XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

  1999cited by this paper
• Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation.

  1998cited by this paper
• UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

  1996cited by this paper
• Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.

  1996cited by this paper
• Global comparison of radiation and chemotherapy dose-response curves with a test for interaction.

  1993cited by this paper
• Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram.

  1989cited by this paper
• Ouabain sensitizes tumor cells but not normal cells to radiation.

  1987cited by this paper
• Mean inactivation dose: a useful concept for intercomparison of human cell survival curves.

  1984cited by this paper
• Mean Inactivation Dose: A Useful Concept for Intercomparison of Human Cell Survival Curves

  1984cited by this paper

• Targeting Chk1 and Wee1 kinases enhances radiosensitivity of 2D and 3D head and neck cancer models to X-rays and low/high-LET protons

  2025cites this paper
• Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

  2025cites this paper
• Improving radiotherapy in pancreatic cancer through radiosensitization strategies.

  2025cites this paper
• Angiotensin II‐induced phosphorylation of CHK1 at serine‐280 drives cardiac remodelling by direct phosphorylation of JAK1, thus activating JAK1‐STAT signalling in murine cardiomyocytes

  2025cites this paper
• Enhanced pharmacological activities of AKR1C3‐activated prodrug AST‐3424 in cancer cells with defective DNA repair

  2024cites this paper
• Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence.

  2024cites this paper
• Combinatorial Approaches for Chemotherapies and Targeted Therapies with Radiation: United Efforts to Innovate in Patient Care.

  2024cites this paper
• Cadmium activates the innate immune system through the AIM2 inflammasome.

  2024cites this paper
• The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy

  2024cites this paper
• Quantitative Chromatin Protein Dynamics During Replication Origin Firing in Human Cells

  2024cites this paper
• Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Potential Benefits of Combining Proton or Carbon Ion Therapy with DNA Damage Repair Inhibitors

  2024cites this paper
• The impact of cathepsins on liver hepatocellular carcinoma: Insights from genetic and functional analyses.

  2024cites this paper
• Novel strategies for tumor radiosensitization mediated by multifunctional gold-based nanomaterials.

  2023cites this paper
• Heavy metal ions exchange driven protein phosphorylation cascade functions in genomic instability in spermatocytes and male infertility

  2023cites this paper
• Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.

  2023cites this paper
• Double‐strand DNA break repair: molecular mechanisms and therapeutic targets

  2023cites this paper
• BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1

  2023cites this paper
• Targeting the DNA Damage Response for Cancer Therapy

  2023cites this paper
• DNA Repair and Therapeutic Strategies in Cancer Stem Cells

  2023cites this paper
• Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence

  2023cites this paper
• Replisome dysfunction upon inducible TIMELESS degradation synergizes with ATR inhibition to trigger replication catastrophe

  2023cites this paper
• Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

  2022cites this paper
• Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives

  2022cites this paper
• Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells

  2022cites this paper
• Targeting replication stress in cancer therapy

  2022cites this paper
• KRCC1, a modulator of the DNA damage response

  2022influential citation
• DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions

  2022cites this paper
• CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer

  2022cites this paper
• H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models

  2022cites this paper
• Pharmacological targeting of differential DNA repair, radio-sensitizes WRN-deficient cancer cells in vitro and in vivo.

  2021cites this paper
• Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma

  2021cites this paper
• Translation of DNA damage response inhibitors as chemoradiation sensitizers from the laboratory to the clinic.

  2021cites this paper
• Targeted therapy for pancreatic cancer: lessons learned and future opportunities

  2021cites this paper
• CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

  2021cites this paper
• Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

  2021cites this paper
• Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

  2021cites this paper
• Expanding roles of cell cycle checkpoint inhibitors in radiation oncology

  2021cites this paper
• RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes

  2021cites this paper
• DNA damage response and repair in pancreatic cancer development and therapy.

  2021cites this paper
• Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

  2021cites this paper
• Targeting DNA repair pathway in cancer: Mechanisms and clinical application

  2021cites this paper
• The Sm core components of small nuclear ribonucleoproteins promote homologous recombination repair.

  2021cites this paper
• Shift in G1-Checkpoint from ATM-Alone to a Cooperative ATM Plus ATR Regulation with Increasing Dose of Radiation

  2021cites this paper
• Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies

  2021cites this paper
• Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention

  2021cites this paper
• Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures

  2021cites this paper
• Dynamics and competition of CRISPR–Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing

  2021cites this paper
• Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer.

  2021cites this paper
• Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents

  2021cites this paper
• Hepatocyte nuclear factor 1 beta: A perspective in cancer

  2021cites this paper
• Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines

  2021influential citation
• Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia

  2021cites this paper
• Reality CHEK: Understanding the biology and clinical potential of CHK1.

  2020cites this paper
• Targeting DNA repair in combination with radiotherapy in pancreatic cancer: A systematic review of preclinical studies.

  2020cites this paper
• Targeting the DNA Damage Response for Radiosensitization

  2020cites this paper
• Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic Cancer

  2020cites this paper
• Targeting DNA Repair Pathways in Hematological Malignancies

  2020cites this paper
• A tiered female ovarian toxicity screening identifies toxic effects of checkpoint kinase 1 inhibitors on murine growing follicles.

  2020influential citation
• Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.

  2020cites this paper
• Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells

  2020cites this paper
• Downregulation of CDC20 Increases Radiosensitivity through Mcl-1/p-Chk1-Mediated DNA Damage and Apoptosis in Tumor Cells

  2020cites this paper
• Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma

  2020cites this paper
• Moving Forward in Cervical Cancer - Enhancing Susceptibility to DNA Repair Inhibition and Damage: NCI Clinical Trials Planning Meeting Report.

  2020cites this paper
• Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation

  2020influential citation
• Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.

  2020cites this paper
• Combining Chk1/2 inhibition with radiation in head and neck cancer

  2020cites this paper
• Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers

  2020cites this paper
• Systematic functional identification of cancer multi-drug resistance genes

  2020cites this paper
• Combination of CHEK1/2 Inhibition and Ionizing Radiation Results in Abscopal Tumor Response through Increased Micronuclei Formation

  2020cites this paper
• Acetyl‐macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti‐cancer effects with the Chk1/2 inhibitor AZD7762

  2019cites this paper
• Mechanistic Modelling of Radiation Responses

  2019cites this paper
• Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death

  2019cites this paper
• A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types

  2019cites this paper
• Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.

  2019cites this paper
• Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting

  2019cites this paper
• Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches

  2019cites this paper
• The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

  2019influential citation
• Enhancing treatment response to neo-adjuvant radiation therapy in oesophageal cancer using novel dual action drugs targeting tumour energy metabolism and angiogenesis

  2019influential citation
• Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair

  2019cites this paper
• Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer

  2019cites this paper
• DNA end-resection in highly accessible chromatin produces a toxic break

  2019cites this paper
• Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells

  2019cites this paper
• A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.

  2019cites this paper
• Chk1 phosphorylated at serine 345 is a predictor of early local recurrence and radio-resistance in breast cancer

  2018cites this paper
• Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer

  2018cites this paper
• Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence.

  2018cites this paper
• CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications

  2018cites this paper
• Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma

  2018cites this paper
• The Inhibition of DNA Damage Response Contributes to Cancer Radiotherapy

  2018cites this paper
• ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors

  2018cites this paper
• NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.

  2018cites this paper
• PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

  2018cites this paper
• Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects

  2018cites this paper
• Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma

  2017cites this paper
• Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

  2017cites this paper
• DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

  2017cites this paper
• Claspin functions in cell homeostasis-A link to cancer?

  2017cites this paper